{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:14:24Z","timestamp":1791342864697,"version":"4.3.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n The voriconazole and echinocandin combination has been found to be synergistic in vitro and in vivo against most Aspergillus fumigatus isolates, both with a WT azole phenotype and an azole-resistant phenotype. The interaction between isavuconazole and echinocandins is less well studied. This is especially true for azole-resistant isolates.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n We investigated the in vitro interaction between isavuconazole and anidulafungin for 30 A. fumigatus isolates including 18 azole-resistant isolates with various isavuconazole resistance phenotypes.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The isavuconazole\/anidulafungin interaction was studied by using an adapted EUCAST-based 2D (12\u205f\u00d7\u205f8) chequerboard broth microdilution colorimetric assay using XTT. The interaction was analysed by FIC index (FICi) analysis and Bliss independence (BI) interaction analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Both the FICi analysis and the BI analysis showed synergistic interaction between isavuconazole and anidulafungin for the majority of WT and azole-resistant isolates. As we did not see significant beneficial effects of combination therapy in TR46\/Y121F\/T289A isolates at clinically achievable drug concentrations, it is unlikely that TR46\/Y121F\/T289A infections would benefit from isavuconazole and anidulafungin combination therapy.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In regions with high azole resistance rates this combination may benefit patients with WT disease, azole-resistant invasive aspergillosis and those with mixed azole-susceptible and azole-resistant infection, but may not be beneficial for aspergillosis due to isolates with high isavuconazole resistance, such as TR46\/Y121F\/T289A isolates.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/jac\/dkaa185","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T15:10:07Z","timestamp":1587395407000},"page":"2582-2586","source":"Crossref","is-referenced-by-count":9,"title":["In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-0778","authenticated-orcid":false,"given":"J B","family":"Buil","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands"},{"name":"Center of Expertise in Mycology Radboudumc\/CWZ, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-725X","authenticated-orcid":false,"given":"R J M","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"Center of Expertise in Mycology Radboudumc\/CWZ, Nijmegen, The Netherlands"},{"name":"Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6422-9862","authenticated-orcid":false,"given":"L","family":"Bedin Denardi","sequence":"additional","affiliation":[{"name":"Programa de P\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias Farmac\u00eauticas, Centro de Ci\u00eancias da Sa\u00fade, Universidade Federal de Santa Maria, Santa Maria, RS, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-2230","authenticated-orcid":false,"given":"W J G","family":"Melchers","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands"},{"name":"Center of Expertise in Mycology Radboudumc\/CWZ, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8600-9860","authenticated-orcid":false,"given":"P E","family":"Verweij","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands"},{"name":"Center of Expertise in Mycology Radboudumc\/CWZ, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"key":"2020082404573567400_dkaa185-B1","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"2020082404573567400_dkaa185-B2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2020082404573567400_dkaa185-B3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020082404573567400_dkaa185-B4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"2020082404573567400_dkaa185-B5","doi-asserted-by":"crossref","first-page":"E103","DOI":"10.3390\/jof4030103","article-title":"Itraconazole, voriconazole, and posaconazole CLSI MIC distributions for wild-type and azole-resistant Aspergillus fumigatus isolates","volume":"4","author":"Buil","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"2020082404573567400_dkaa185-B6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jac\/dku364","article-title":"Azole, polyene and echinocandin MIC distributions for wild-type, TR34\/L98H and TR46\/Y121F\/T289A Aspergillus fumigatus isolates in the Netherlands","volume":"70","author":"van Ingen","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020082404573567400_dkaa185-B7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21-22","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"2020082404573567400_dkaa185-B8","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1128\/AAC.49.3.1232-1235.2005","article-title":"Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus","volume":"49","author":"Cuenca-Estrella","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404573567400_dkaa185-B9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.diagmicrobio.2012.02.003","article-title":"In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus","volume":"73","author":"Krishnan-Natesan","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020082404573567400_dkaa185-B10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jac\/dks402","article-title":"Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis","volume":"68","author":"Seyedmousavi","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020082404573567400_dkaa185-B11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1128\/AAC.00980-12","article-title":"In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus","volume":"57","author":"Seyedmousavi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404573567400_dkaa185-B12","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkw276","article-title":"Dose optimization of voriconazole\/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic\/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis","volume":"71","author":"Siopi","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020082404573567400_dkaa185-B13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1469-0691.2004.00958.x","article-title":"Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis","volume":"10","author":"Chandrasekar","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"2020082404573567400_dkaa185-B14","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/AAC.46.8.2564-2568.2002","article-title":"Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis","volume":"46","author":"Kirkpatrick","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404573567400_dkaa185-B15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11046-013-9719-z","article-title":"Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species","volume":"177","author":"Zhang","year":"2014","journal-title":"Mycopathologia"},{"key":"2020082404573567400_dkaa185-B16","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1128\/AAC.49.12.4867-4875.2005","article-title":"Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis","volume":"49","author":"Clemons","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404573567400_dkaa185-B17","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1128\/AAC.00045-12","article-title":"In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp","volume":"56","author":"Planche","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404573567400_dkaa185-B18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.diagmicrobio.2018.03.003","article-title":"In vitro combination of voriconazole with micafungin against azole-resistant clinical isolates of Aspergillus fumigatus from different geographical regions","volume":"91","author":"Fakhim","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020082404573567400_dkaa185-B19","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1128\/AAC.00329-09","article-title":"Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis","volume":"53","author":"Petraitis","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404573567400_dkaa185-B20","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2020082404573567400_dkaa185-B21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2009.334","article-title":"Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: a European Organisation for Research and Treatment of Cancer study","volume":"45","author":"Herbrecht","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2020082404573567400_dkaa185-B22","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2020082404573567400_dkaa185-B23","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1128\/AAC.03261-14","article-title":"In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds","volume":"58","author":"Katragkou","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404573567400_dkaa185-B24","doi-asserted-by":"crossref","first-page":"e01382","DOI":"10.1128\/AAC.01382-17","article-title":"In vitro combination of isavuconazole with echinocandins against azole-susceptible and -resistant Aspergillus spp","volume":"62","author":"Raffetin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404573567400_dkaa185-B25","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1469-0691.2008.02086.x","article-title":"EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds","volume":"14","author":"Rodriguez-Tudela","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"2020082404573567400_dkaa185-B26"},{"key":"2020082404573567400_dkaa185-B27","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1128\/AAC.01160-06","article-title":"Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species","volume":"51","author":"Antachopoulos","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404573567400_dkaa185-B28","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/JCM.39.9.3402-3408.2001","article-title":"Colorimetric assay for antifungal susceptibility testing of Aspergillus species","volume":"39","author":"Meletiadis","year":"2001","journal-title":"J Clin Microbiol"},{"key":"2020082404573567400_dkaa185-B29","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1128\/AAC.04469-14","article-title":"The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus","volume":"59","author":"Mavridou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404573567400_dkaa185-B30","first-page":"457","article-title":"Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis","volume":"55","author":"Martin-Vicente","year":"2017","journal-title":"Med Mycol"},{"key":"2020082404573567400_dkaa185-B31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diagmicrobio.2017.10.004","article-title":"Evaluation of the efficacy of a posaconazole and anidulafungin combination in a murine model of pulmonary aspergillosis due to infection with Aspergillus fumigatus","volume":"90","author":"Bedin Denardi","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020082404573567400_dkaa185-B32","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1128\/AAC.00833-13","article-title":"Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404573567400_dkaa185-B33","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1128\/AAC.47.4.1416-1418.2003","article-title":"In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points","volume":"47","author":"Shalit","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404573567400_dkaa185-B34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/9\/2582\/33665073\/dkaa185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/9\/2582\/33665073\/dkaa185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T04:57:52Z","timestamp":1598245072000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/9\/2582\/5855124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,6,9]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa185","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,6,9]]}}}